Venetoclax

Form: Tablet

Strength: 10 mg, 50 mg, 100 mg

Reference Brands: Venclexta® (EU & US)

Category: Oncology Cancer Care

Venetoclax Tablets are a targeted oral therapy used in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). As a potent BCL-2 inhibitor, Venetoclax promotes apoptosis in cancer cells by restoring programmed cell death pathways. Marketed under the brand name Venclexta®, it is available in 10 mg, 50 mg, and 100 mg strengths. Manufactured under GMP-certified facilities, Venetoclax offers a reliable oncology solution for B2B pharmaceutical partners across the US and EU, supporting effective cancer treatment strategies with proven clinical outcomes.